Glycostem is delighted that we have been listed as the only not-public listed company in this article. If you are interested in the NK cell space, this is a recommended read.
October 2-5, 2016
Glycostem presented their recent advances in NK cell therapy for hematological and solid cancers at NK 2016.
September 19-22, 2016
Glycostem's CSO, Dr. Jan Spanholtz, has been invited as speaker at the 14th Annual Discovery on Target Event, Boston, USA
June 27-28, 2016
Dr. Jan Spanholtz (CSO) presents at the 5th Clinical Trials Innovation Programme Conference (CTIP), Hamburg, Germany
June 6-9, 2016
Dr. Wim Jongen (CEO) represents Glycostem at the BIO International Convention in San Francisco, USA
June 2, 2016
Dr. Jan Spanholtz (CSO) gives a presentation on Innovative Cellular Medicine at the Health Valley Event Exit Oss: 'Crossing Borders', Pivot Park, Oss, The Netherlands
May 16-18, 2016
Dr. Jan Spanholtz (CSO) presents results of clinical phase I study at the Innate Killer Summit, San Diego, USA
April 20, 2016
On the 20th of April 2016, the FDA Office of Orphan Products Development has granted orphan drug designation to Glycostem's NK Cell Product oNKord® for treatment of acute myeloid leukemia (AML)
March 1-3, 2016
Glycostem's CSO, Dr. Jan Spanholtz presents clinical phase I data at the Adopt Summit 2016: Adoptive Immunotherapy, London, UK
Jan 11-13, 2016
Glycostem will be represented at Biotech Showcase, the 8th Annual Biotechnology Investor and Partnering Conference, San Francisco, USA.
Wim Jongen (CEO) and Jan Spanholtz (CFO) will participate.
December 4-8, 2015
Glycostem together with Radboud University Medical Center presents results of their Phase I clinical trial in AML patients at the 57th ASH Annual Meeting, Orlando, USA
Poster presentation by Dr. Harry Dolstra and Dr. Jan Spanholtz
November 2-4, 2015
Glycostem's CEO, Dr. Wim Jongen, gives a company presentation at Bio-Europe, Munich, Germany
October 7-9, 2016
Dr. Jan Spanholtz and John Veluchamy attend the Natural Killer Cell Symposium, Göttingen, Germany. John Veluchamy (PhD fellow) will present a poster at this meeting.
September 29-30, 2015
Glycostem's CEO, Dr. Wim Jongen, gives a company presentation at 15th Annual Biotech in Europe Forum, Basel, Switzerland
July 9, 2015
Glycostem's CSO, Dr. Jan Spanholtz, gives a presentation on Cell Therapy in Oncology at the Health Valley Event Exit Oss, Pivot Park, Oss, The Netherlands
May 2-6, 2015
Glycostem's CSO, Dr. Jan Spanholtz, presents Poster at NK2015, 15th Annual Meeting of the Society for Natural Immunity, Montebello, Québec, Canada
On the 2nd December Glycostem has officially launched its new website, which provides a comprehensive overview of our current position and ambitious plans on the application of NK cell immunotherapy in the treatment of cancer.Read more >
ODD for NK Cell Product oNKord® to treat AMLRead more >
New home for Glycostem's R&DRead more >